Please ensure Javascript is enabled for purposes of website accessibility

How You Can Profit From the Next Big Thing in Healthcare

By Keith Speights - Updated Mar 16, 2017 at 12:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Precision medicine is going to be huge. Two stocks in particular -- Illumina and Roche -- provide investors a way to profit.

What's the next big thing coming for healthcare?

Results from the New England Journal of Medicine (NEJM) Catalyst Insights Survey on Care Redesign suggest that genomics and patient-generated data critical for precision medicine could surge in importance over the next five years. Savvy investors could profit from this increased demand for precision medicine data by buying two specific stocks: Illumina (ILMN 0.20%) and Roche (RHHBY 4.07%). Here's why.  

Man pointing to screen with healthcare symbols

Image source: Getty Images.

The next generation of next-generation sequencing

Mapping the first human genome cost somewhere between $500 million and $1 billion, according to the National Human Genome Research Institute. Illumina's HiSeq next-generation sequencing system, first introduced in 2010, brought the cost of mapping a human genome down to $1,000. Now Illumina is launching the next generation in next-generation sequencing systems: NovaSeq.

Illumina CEO Francis deSouza predicts that the NovaSeq architecture will pave the way for a $100 genome. Even before that milestone is achieved, NovaSeq's lower per-sample consumable costs should allow laboratories that couldn't afford sequencing technology in the past an option to map human genomes for around $1,000 each -- potentially fueling the growth of precision medicine. 

Probably no company has impacted the field of genomic sequencing as much as Illumina. First incorporated in 1998, Illumina now claims nearly 10,000 sequencing systems in use across the world -- from the lower-throughput and lower-cost MiniSeq to the top-end HiSeq X system. The launch of NovaSeq positions Illumina to continue its dominance in genomic sequencing. 

Illumina stock isn't cheap. Shares currently trade at a whopping 54 times trailing earnings. Investors shouldn't be too afraid of that high valuation, though. It's actually on the lower end of the historical earnings multiple range for Illumina. If demand for precision medicine grows as expected, Illumina should be one of the primary beneficiaries.

Covering both key parts of precision medicine 

Precision medicine involves diagnostics and development. Diagnostics are needed to determine the genetic profiles of patients. But without development of drugs that target specific genetic variations, precision medicine wouldn't be possible. Roche covers both.

Roche's diagnostics business segment markets instruments and tests that allow doctors to quickly determine appropriate treatment decisions. The healthcare giant is also at the forefront of developing precision medicines. Roche's Herceptin was the first precision medicine on the market, gaining U.S. regulatory approval in 1998.

The company's Genentech Research and Early Development (gRED) group is leveraging Roche's expertise in biomarkers (molecules found in blood, other body fluids, or tissues that can point to annormalities or diseases) and diagnostics to identify the best combinations of drugs for treating specific diseases. Roche is using this approach in a significant way with its cancer drug Tecentriq, which is being evaluated as a backbone for multiple combination therapies. 

Tecentriq is just one of several drugs that could drive growth for Roche in the coming years. Sales are soaring for another cancer drug, Perjeta, as well as for autoimmune disease drug Actemra and anti-inflammatory Xolair. Roche should also enjoy success with multiple sclerosis drug Ocrevus, which awaits regulatory approval. 

There are some major hurdles for the company, however. MabThera/Rituxan already faces biosimilar competition in Europe. Roche's recent deal with Mylan clears the way for biosimilar rivals for Herceptin in the near future. Avastin loses patent exclusivity in 2020. The three drugs are Roche's biggest moneymakers right now. 

Bigger precision medicine winner?

Both Illumina and Roche should profit from the expansion of precision medicine. Which company will be the bigger winner? I'd go with Illumina.

Illumina is about as pure-play as you can get for precision medicine. Back in the gold rush days, the ones who made the most money weren't the gold miners but rather the merchants who sold the shovels to the miners. That's essentially what Illumina does for precision medicine. Its genomic sequencing systems are the shovels that make precision medicine possible.

I don't think Illumina's share price will skyrocket nearly 1,000% like it did over the last 10 years. However, if you're looking to profit from the next big thing in healthcare, Illumina is probably the best pick on the market.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina, Inc. Stock Quote
Illumina, Inc.
$193.93 (0.20%) $0.38
Roche Holding AG Stock Quote
Roche Holding AG
$41.64 (4.07%) $1.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.